Abstract: A method is described for characterization of the quality of a sialoglycoprotein via its isoform number I which is calculated from the isoform distribution of the capillary electrophoretic analysis of the sialoglycoprotein and represents a quality feature for the batch consistency, storage stability, biological half-life and the biological effectiveness of a therapeutic glycoprotein. Uses of this method are also described.

Abstract: A method is described for characterisation of the quality of a sialoglycoprotein via its isoform number I which is calculated from the isoform distribution of the capillary electrophoretic analysis of the sialoglycoprotein and represents a quality feature for the batch consistency, storage stability, biological half-life and the biological effectiveness of a therapeutic glycoprotein. Uses of this method are also described.

Abstract: A method for the qualitative and quantitative determination of multimers of fibrinogen and of von Willebrand factor by gel electrophoresis, in which a sample containing von Willebrand factor (vWF) or fibrinogen is fractionated by submarine electrophoresis using a continuous, homogeneous agarose gel free of lumps, and the multimer bands are visualized immunochemically after a western blot analysis by a specific antibody-enzyme conjugate on the blotting membrane or by a suitable dye, preferably with a blue stain, in the gel, is described.

Abstract: A method for the production of a polypeptide, the method comprising culturing, under conditions which allow for the expression of DNA encoding SEQ ID NO:2 in an eukaryotic host cell, wherein the DNA is in vector pPHOEBE-40-7, and optionally isolating the polypeptide from the culture, is described. A polypeptide obtained by such method and a pharmaceutical composition comprising the polypeptide also are described. A composition for diagnosing anemia comprising such polypeptide and a method of treating anemia caused by lack of erythropoietin also are described.

Abstract: The present invention involves a process for characterizing the glycosylation of glyco-proteins and an in vitro process for determining the bioavailability of glyco-proteins, based on the "hypothetical charge number" (or N) and usable for both endogenic and exogenic glyco-proteins.

Abstract: The invention relates to monoclonal antibodies (mAB) which bind to water-soluble complexones such as ethylenediamine tetraacetate (EDTA) or diethylenetriamine pentaacetate (DTPA) with high specificity and avidity and retain their high avidity and specificity for these complexones after complexing of EDTA or DTPA with metal ions. These mAB can therefore be used, e.g. coupled on filters or other supports, for removing toxic heavy metals which are complexed with EDTA or DTPA. Furthermore, these mAB are suitable as components of immunoassays (RIA, ELISA etc.) for the quantitative determination of EDTA or DTPA in aqueous solutions.

Abstract: The invention relates to monoclonal antibodies (mAB) which bind to water-soluble complexones such as ethylenediamine tetraacetate (EDTA) or diethylenetriamine pentaacetate (DTPA) with high specificity and avidity and retain their high avidity and specificity for these complexones after complexing of EDTA or DTPA with metal ions. These mAB can therefore be used, e.g. coupled on filters or other supports, for removing toxic heavy metals which are complexed with EDTA or DTPA. Furthermore, these mAB are suitable as components of immunoassays (RIA, ELISA etc.) for the quantitative determination of EDTA or DTPA in aqueous solutions.

Abstract: Compounds from biopolymers and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof.The invention relates to compounds from biopolymers and effector substances which are linked with the aid of derivatives of optically active amino acids in which the amino group has been converted into a maleimido group and the carboxyl group into an active easter group.

Abstract: Compounds from biopolymers and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof. The invention relates to compounds from biopolymers and effector substances which are linked with the aid of derivatives of optically active amino acids in which the amino group has been converted into a maleimido group and the carboxyl group into an active ester group.

Abstract: The invention relates to magnetic protein conjugates of the formula I ##STR1## in which M represents a dispersible magnetically reacting material or particle which carries aminogroups, Ig represents a protein which carries one or more mercapto groups, and X represents an organic chemical structure which links the two ligands by chemical means, to a process for the preparation of protein conjugates of the formula I, and to the use of conjugates of this type for removing cells or soluble bioorganic molecules or components from aqueous salt solutions or body fluids, and to the use thereof within the framework of a diagnostic method or as a diagnostic aid.

Abstract: The invention relates to a method of using a pair of leucine zipper peptides for in vitro diagnosis, in particular, for the immunochemical detection and determination of an analyte in a biological liquid. In one method, the first leucine zipper peptide is immobilized by attaching it to a solid support, the second leucine zipper peptide is coupled to a specific binding partner for the analyte, the two peptides are brought into contact, the sample of the biological liquid is brought into contact with the immobilized first peptide and the specific binding partner for the analyte, and the amount of analyte bound to the binding partner is determined. The leucine zipper peptides are preferably v-fos and c-jun.

Abstract: The invention relates to bispecific and oligospecific, mono- and oligovalent receptors which are prepared by gene manipulation by fusion of DNA coding for F(ab) fragments of antibodies of two or more different specificities by means of suitable linkers. In this connection, one specificity is preferably directed either against an epitope, which is located on the cell membrane or in the interstitium, of a tumor-associated antigen (TAA) or against an epitope in the tumor endothelium (TE), while the other specificities relate to high-molecular or low-molecular weight ligands and react, for example, with the Komplexons ethylenediaminetetraacetate and diethylenetriaminepentaacetate in Y90 complexed form (EDTA-Y90 and DTPA-Y90 respectively). In a particularly preferred embodiment, the binding with the Komplexons takes place on the Komplexon receptor arm via fos-jun interaction (or else avidin-biotin interaction). Other preferred specificities have catalytic properties.

Abstract: The invention relates to compounds from biopolymers and effector substances which are linked with the aid of derivatives of optically active amino acids in which the amino group has been converted into a maleimido group and the carboxyl group into an active ester group, processes for the preparation thereof and the use thereof.

Abstract: The invention relates to compounds from biopolymers and effector substances which are linked with the aid of derivatives of optically active amino acids in which the amino group has been converted into a maleimido group and the carboxyl group into an active ester group.

Abstract: The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, ##STR1## which can optionally also be in the form of an acid addition salt of physiologically acceptable inorganic or organic acids, where R.sup.1 is hydrogen or a hydroxyl group, R.sup.2 is hydrogen, a hydroxyl or a methoxy group, R.sup.3 is hydrogen or a hydroxyl group, R.sup.4 is hydrogen or a hydroxyl group, R.sup.5 hydrogen, a hydroxyl or a methoxycarbonyl group, R.sup.6 is CH.sub.2 CH.sub.3, COCH.sub.3, COCH.sub.2 OH, CHOHCH.sub.3 or CHOHCH.sub.2 OH and R.sup.

Abstract: The invention relates to magnetic protein conjugates of the formula IM--NH--CO--(CH.sub.2).sub.n --S--P' Iwith n=1-6, preferably with a n=1 or 2 and particularly preferably with n=1, in which M is a dispersible, magnetically reacting material or particle which carries amino groups, and P' is a protein, to a process for the preparation thereof and to the use thereof for the specific removal of cells or soluble antigens, receptors, substrates, cofactors or carbohydrate determinants from aqueous salt solutions or body fluids or as part of a diagnostic method or as a diagnostic aid, preferably for the removal of cells, preferably for bone marrow depletion or for HLA typing.

Abstract: The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I ##STR1## wherein R.sup.1 is a CH.sub.3 (CH.sub.2).sub.n group with n=0 to 3,R.sup.2 is a hydrogen atom or a methyl group,R.sup.3 is a hydrogen atom, a methyl group or an acyl protective group, andR.sup.4 is a hydrogen atom or an acyl protective group,and which are optionally in the form of a salt of an inorganic or organic acid, to a process for their preparation and to their use in pharmaceuticals.

Abstract: The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, which are optionally in the form of a salt of an inorganic or organic acid, ##STR1## in which the substituents have the following meaning: R.sup.1 is hydrogen or a hydroxyl group,R.sup.2 is hydrogen or a hydroxyl or a methoxy group,R.sup.3 is hydrogen or a hydroxyl group,R.sup.4 is hydrogen or a hydroxyl group,R.sup.5 is hydrogen, a hydroxyl or a methoxycarbonyl group, or a substituent of the general formula II, ##STR2## in which R.sup.8a has the meaning indicated for R.sup.8, or a substituent of the formula III, ##STR3## R.sup.6 is ethyl, methylcarbonyl, hydroxymethylcarbonyl, hydroxyalkyl or a dihydroxyalkyl,R.sup.7 is hydrogen or a substituent of the general formula IV, ##STR4## and R.sup.8 is hydrogen or a cyanomethyl group or a substituent of the general formula COR.sup.9 or CH.sub.2 R.sup.10, R.sup.9 being hydrogen, CH.sub.3, CF.sub.3 or CCl.sub.3, and R.sup.10 being C.sub.1 - to C.sub.

Abstract: The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I ##STR1## in which the radicals R.sup.1 is hydrogen or a hydroxyl group, R.sup.2 is hydrogen or a hydroxyl group or a structure of the formula II, and R.sup.3 is a hydroxyl group or a structure of the formula II ##STR2## in which R.sup.4 is an aliphatic or aromatic acyl group, with the proviso that at least one of the radicals R.sup.2 and R.sup.3 has a structure of the formula II, which are optionally in the form of a salt of an inorganic or organic acid, as well as to the process for the preparation thereof, and to the use thereof in pharmaceuticals.